ICER report calls for 90% price drop on tardive dyskinesia drugs

22 November 2017
2019_biotech_test_vial_discovery_big

A damning assessment of the cost-benefit of vesicular monoamine transporter-2 (VMAT2) inhibitors for management of tardive dyskinesia (TD) has been released by USA-based not-for-profit Institute for Clinical and Economic Review (ICER).

The  Evidence Report assessed the comparative clinical effectiveness and value of three treatments for TD, a movement disorder often associated with long-term use of certain antipsychotic drugs.

"Current prices are far out of alignment with the benefits measured in clinical trials"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology